General pathways and personalized risk of morbidity after sepsis
脓毒症后发病的一般途径和个性化风险
基本信息
- 批准号:8950589
- 负责人:
- 金额:$ 19.43万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-08-15 至 2019-07-31
- 项目状态:已结题
- 来源:
- 关键词:AccountingAcuteAcute Kidney FailureAdultAmericanAwardBig DataBiometryCaringCatalogingCatalogsCessation of lifeChargeChronicChronic DiseaseChronic Obstructive Airway DiseaseClinical DataClinical ManagementClinical ResearchCohort StudiesCritical CareCritical IllnessDataDevelopmentDiagnosisDiseaseDoctor of PhilosophyEnsureEnvironmentEpidemicEpidemiologyFaceFailureFoundationsGoalsHealthHealthcareHeart failureHeatingHospitalizationHospitalsImpaired cognitionIncidenceIndividualInfectionInflammationInpatientsInterventionLaboratoriesLeadLeftLiteratureLogistic RegressionsLungMapsMedicareMental DepressionMentorsMethodologyMichiganModelingMorbidity - disease rateOutcomeOutpatientsPathway interactionsPatient CarePatient riskPatientsPhasePhysiciansPhysiologicalPopulationProceduresProcessProductivityPublic HealthPulmonary InflammationQuality of lifeRecoveryRecurrenceRehabilitation therapyRelative (related person)ResearchResearch DesignResearch PersonnelRiskSamplingScienceScientistSepsisSiteStatistical MethodsStatistical ModelsSterilitySurvivorsSystemTechniquesTestingTimeTrainingUniversitiesVeteransWorkadverse outcomebeneficiarycareercareer developmentclinical epidemiologyclinically relevantexperienceforesthealth administrationimplementation scienceimprovedinnovationmodel buildingmortalitypersonalized medicinepredictive modelingpreventskillstoolusability
项目摘要
DESCRIPTION (provided by applicant): This K08 proposal will complete Hallie Prescott, MD; MSc's training towards her long-term career goal of improving the long-term survival and quality of life of critical illness survivors. Dr. Prescott is a pulmonary & critical care physician and scientist at the University of Michigan, with Master's training in clinical study design and biostatistics. This proposal builds on Dr. Prescott's prior experience, leveraging advanced statistical methods, granular clinical data, and the rich training environment at University of Michigan to improve our understanding and management of post-sepsis morbidity. The research will be completed under the guidance of primary mentor Theodore J. Iwashyna, MD, PhD, co-mentor Kenneth Langa, MD, PhD, and co-mentor Richard Gonzalez, PhD, with a planned mentor-the-mentor strategy and additional input from an advisory board of physician-scientists. This 5-year plan includes formal coursework, professional development, and mentored research, with defined milestones to ensure productivity and a successful transition to independence. This mentored research has 2 specific Scientific Aims: AIM 1: Test the relative importance 3 competing hypotheses for the general pathway of post- sepsis morbidity. * AIM 2: Develop a diagnosis-specific readmission risk profile tool to personalize treatment for severe sepsis survivors in the immediate (90-day) post-hospital setting. Inherent to completing these high-level Aims, Dr. Prescott will also (1) characterize the epidemiology of multi- morbidity and hospitalization in severe sepsis survivors, (2) identify the health conditions most increased after
severe sepsis, (3) define the incremental benefits of specific clinical data in improving risk prediction, (4) compare the accuracy and usability of complementary cutting edge personalized prediction methodologies. This work will build to at least two R01 proposals: (1) to examine the mechanism by which a specific chronic health condition is increased after severe sepsis (as identified in Aim 1) or to examine how post-sepsis morbidity differs from that of less-severe infections and sterile inflammation, and (2) to implement and evaluate the diagnosis-specific risk profile tool developed in Aim 2. Beyond establishing the foundation for a programmatic line of research to improve the care of severe sepsis survivors, this proposal will provide Dr. Prescott with research skills that are readily applicable to additional domains of critical illness research In short, this K08 award will support and accelerate the career development activities of Dr. Prescott and allow her to successfully launch into the next phase of her career as an independent investigator.
描述(由申请人提供):本 K08 提案将完成医学博士哈莉·普雷斯科特 (Hallie Prescott) 的培训,以实现她改善危重疾病幸存者的长期生存和生活质量的长期职业目标。密歇根大学的护理医师和科学家,接受过临床研究设计和生物统计学的硕士学位培训。该提案建立在 Prescott 博士先前的经验基础上,利用先进的统计方法、精细的临床数据和密歇根大学丰富的培训环境可提高我们对脓毒症后发病率的理解和管理该研究将在主要导师 Theodore J. Iwashyna(医学博士、博士)和联合导师 Kenneth Langa(医学博士、博士)的指导下完成。和联合导师理查德·冈萨雷斯博士,制定了导师对导师策略,并得到了医生科学家顾问委员会的额外投入。这个五年计划包括正式课程、专业发展和指导研究,确定了确保生产力和成功过渡到独立的里程碑。 这项指导性研究有 2 个具体的科学目标: 目标 1:测试脓毒症后发病一般途径的 3 个相互竞争的假设的相对重要性 * 目标 2:制定特定的诊断。 Prescott 博士还将 (1) 描述再入院风险概况工具,用于在出院后立即(90 天)对严重败血症幸存者进行个性化治疗。严重脓毒症幸存者的多重发病率和住院治疗的流行病学,(2) 确定治疗后增加最多的健康状况
严重脓毒症,(3) 定义特定临床数据在改善风险预测方面的增量效益,(4) 比较互补的尖端个性化预测方法的准确性和可用性这项工作将构建至少两个 R01 提案:(1)检查严重脓毒症后特定慢性健康状况恶化的机制(如目标 1 中确定的)或检查脓毒症后发病率与不太严重的感染和无菌性炎症的发病率有何不同,以及 (2) 实施和评估目标 2 中开发的诊断特定风险概况工具。除了为改善严重脓毒症幸存者护理的计划性研究奠定基础之外,该提案还将为 Prescott 博士提供可轻松应用于其他关键领域的研究技能简而言之,这个 K08 奖项将支持和加速 Prescott 博士的职业发展活动,并使她能够作为一名独立研究者成功进入职业生涯的下一阶段。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Hallie Christine Prescott其他文献
Hallie Christine Prescott的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Hallie Christine Prescott', 18)}}的其他基金
Optimizing Veteran Recovery from Sepsis (OVeR-Sepsis)
优化脓毒症退伍军人康复 (OVeR-脓毒症)
- 批准号:
10311252 - 财政年份:2021
- 资助金额:
$ 19.43万 - 项目类别:
Optimizing Veteran Recovery from Sepsis (OVeR-Sepsis)
优化脓毒症退伍军人康复 (OVeR-脓毒症)
- 批准号:
10496554 - 财政年份:2021
- 资助金额:
$ 19.43万 - 项目类别:
Benchmarking Hospital Quality: Template Matching versus Conventional Regression Approaches
医院质量基准测试:模板匹配与传统回归方法
- 批准号:
10308540 - 财政年份:2018
- 资助金额:
$ 19.43万 - 项目类别:
Benchmarking Hospital Quality: Template Matching versus Conventional Regression Approaches
医院质量基准测试:模板匹配与传统回归方法
- 批准号:
9679239 - 财政年份:2018
- 资助金额:
$ 19.43万 - 项目类别:
Benchmarking Hospital Quality: Template Matching versus Conventional Regression Approaches
医院质量基准测试:模板匹配与传统回归方法
- 批准号:
10186545 - 财政年份:2018
- 资助金额:
$ 19.43万 - 项目类别:
General pathways and personalized risk of morbidity after sepsis
脓毒症后发病的一般途径和个性化风险
- 批准号:
9124922 - 财政年份:2015
- 资助金额:
$ 19.43万 - 项目类别:
相似国自然基金
Tenascin-X对急性肾损伤血管内皮细胞的保护作用及机制研究
- 批准号:82300764
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
活性脂质Arlm-1介导的自噬流阻滞在儿童T细胞急性淋巴细胞白血病化疗耐药逆转中的作用机制研究
- 批准号:82300182
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
PHF6突变通过相分离调控YTHDC2-m6A-SREBP2信号轴促进急性T淋巴细胞白血病发生发展的机制研究
- 批准号:82370165
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
SGO2/MAD2互作调控肝祖细胞的细胞周期再进入影响急性肝衰竭肝再生的机制研究
- 批准号:82300697
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
KIF5B调控隧道纳米管介导的线粒体转运对FLT3-ITD阳性急性髓系白血病的作用机制
- 批准号:82370175
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Shifting paradigms to emerging toxins in freshwater cyanobacterial blooms
淡水蓝藻水华中新出现的毒素的范式转变
- 批准号:
10912318 - 财政年份:2023
- 资助金额:
$ 19.43万 - 项目类别:
Enhancing Research capacity for Sickle Cell Disease and related NCDs across the Lifespan in Uganda. ''Enrich Project''
加强乌干达全生命周期镰状细胞病和相关非传染性疾病的研究能力。
- 批准号:
10665128 - 财政年份:2023
- 资助金额:
$ 19.43万 - 项目类别:
Leveraging a novel health records platform to predict the development of cardiovascular disease following kidney transplantation
利用新型健康记录平台预测肾移植后心血管疾病的发展
- 批准号:
10679322 - 财政年份:2023
- 资助金额:
$ 19.43万 - 项目类别:
Neural and Renal Contributions to Hypertension with Androgen Deprivation Therapy
雄激素剥夺疗法对高血压的神经和肾脏影响
- 批准号:
10662133 - 财政年份:2023
- 资助金额:
$ 19.43万 - 项目类别:
Class II Human Leukocyte Antigen biologics for antibody-mediated graft rejection.
用于抗体介导的移植物排斥反应的 II 类人类白细胞抗原生物制剂。
- 批准号:
10598931 - 财政年份:2023
- 资助金额:
$ 19.43万 - 项目类别: